|
BioScreening - organic compounds for screening
News: CollaborationsiThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer - iThemba Pharmaceuticals’ service division and Pyxis Discovery announced today that they have signed a collaborative agreement to jointly market both companies’ services.
Pyxis’s world class computational chemistry and lead discovery expertise will be coupled with iThemba’s service division to provide medicinal and synthetic chemistry support to projects identified through Pyxis’ international client network. iThemba Pharmaceuticals and [...]
Syntopix edges closer to early revenue streams, announces positive phase II cosmetic study of antimicrobial compound - Specialty antimicrobial research and development company Syntopix (AIM: SYN) took another step closer to commercialising a new product targeting a large consumer healthcare market, reporting good results from the trials of its new compound for the treatment of acneic skin, a condition that affects 85% of the population during their lifetime.
Over the course of the [...]
GSK Signs On Astex in Broad Partnership for About $33M Up Front - GlaxoSmithKline (GSK) has inked a deal with Astex Therapeutics to discover, develop, and commercialize compounds directed against multiple targets for £20 million (about $33 million) up front. Astex is eligible to development and regulatory milestones of over £300 million (roughly $496.47 million) if all programs are successfully developed and commercialized.
The up-front payment comprises £12.5 million [...]
Aeolus Drug Protects the Gastrointestinal Tract in Acute Radiation Syndrome Studies Sponsored by the National Institutes of Health`s National Institute for Allergy and Infectious Diseases - * AEOL 10150 Effectively Increases Regeneration of GI Stem Cells and Reduces the
Severity and Duration of Diarrhea
* Drug Improves Survival When Administered 24 Hours after Total Body
Irradiation
MISSION VIEJO, Calif.--(Business Wire)--
Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS) announced today that recent
experiments in preclinical models conducted by the National Institutes of
Health`s (NIH), National Institute of Allergy and Infectious Diseases [...]
Galapagos expands strategic alliance in metabolic disease with Merck & Co., Inc - * Galapagos to discover small molecule candidate drugs for pre-clinical development in atherosclerosis* Total alliance milestones more than double to over EUR 400 million, plus royalties on worldwide sales
Mechelen, Belgium 14 October 2009 - Galapagos NV (Euronext: GLPG) announced today that it has expanded its global [...]
Evotec, Ono Extend Drug Discovery Services Pact - NEW YORK (GenomeWeb News) – Evotec and Ono Pharmaceutical have extended a research collaboration and have struck a new agreement to study potential drug compounds, Evotec said today.
The companies began their drug target collaboration in March 2008.
Under the agreements, Evotec will provide high-throughput screening, in vitro pharmacology, protein crystallography, and medicinal chemistry services to discover [...]
GenoLogics and CLC bio to Provide End-to-End Genomics Informatics and Analysis for Next Generation Sequencing - Victoria, BC, Canada and Aarhus, Denmark — October 19, 2009 — GenoLogics and CLC bio today announced they will provide an end-to-end informatics and analysis solution, optimized for Next Generation Sequencing research that addresses both lab and data management and data analysis all within one integrated system.
This end-to-end solution will significantly impact researchers’ ability to [...]
DiscoveryBioMed, Inc. Awarded Phase 2 SBIR Grant by the NIH to Discover Hypertension and Cystic Fibrosis (CF) Drugs - BIRMINGHAM, Ala.–(BUSINESS WIRE)–DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the [...]
Zelinsky Institute Inc. announced collaboration with ART-CHEM - Zelinsky Institute Inc. (Newark, DE, August 2009) - Zelinsky Institute Inc. expands its partnership and supplier network with the announcement of collaboration with one of the premier fine chemistry companies - ART-CHEM, which originated from Moscow, Russia, and has started its operations in Berlin, Germany, in 2005. ART-CHEM specializes in synthesis of highly diverse [...]
Evotec Announces Research Agreement With Biogen Idec - HAMBURG, Germany and OXFORD, UK, Sept. 9, 2009 (GLOBE NEWSWIRE) -- Evotec AG
(Frankfurt:EVT) (Nasdaq:EVTC), a leading provider in the discovery and
development of novel small molecule drugs, today announced that it has entered
into a research agreement with Biogen Idec (Nasdaq:BIIB), a leading
biopharmaceutical company headquartered in Cambridge, Mass., USA.
Evotec will use its expertise and technologies in protein [...]
InVivo and CEVEC pharmaceuticals sign license agreement regarding the use of human CAP-Tâ„¢ Technology for production of recombinant proteins - Cologne, Germany, October 01, 2009 / b3c newswire / - CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes and the contract manufacturer InVivo BioTech Services GmbH announced today the signing of a strategic license agreement. This license enables InVivo to offer its customers the production of [...]
BioLeap Wins GlaxoSmithKline Contract to Design Novel Lead Compounds for Previously Intractable Targets for Important Unmet Medical Needs. - BioLeap and GSK have entered into an agreement whereby BioLeap will design novel
lead compounds for "difficult" drug targets. The targets (not disclosed) are
ones for which conventional approaches, like high throughput screening, have
failed to yield a viable chemical starting point. Typically these are in areas
of high unmet medical need.
BioLeap will use its computational fragment-based drug design [...]
National Cancer Institute names Emory to nationwide NCI chemical biology consortium - CBC will support rapid development of innovative, targeted cancer therapies
Emory University’s Chemical Biology Discovery Center has been selected by SAIC-Frederick, Inc. (SAIC-F) to be part of an 11-member national consortium aimed at accelerating the discovery and development of new and innovative, targeted cancer therapies. SAIC-F is the prime contractor to the National Cancer Institute at [...]
Nuevolution Announces Worldwide Technology Cross-Licensing Agreement With GSK - COPENHAGEN, Denmark, July 28 /PRNewswire/ — Nuevolution today announced the execution of a worldwide technology cross-licensing agreement with GlaxoSmithKline.
The agreement relates to a number of patented technologies for rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug [...]
Astellas and REGiMMUNE to Collaborate on New Vaccine Technology - TOKYO and MOUNTAIN VIEW, CA–(Marketwire - July 22, 2009) - REGiMMUNE Corporation today announced that Astellas Pharma Inc. and REGiMMUNE have entered into a collaboration agreement to jointly research and develop a novel vaccine-platform technology. The partnership will combine Astellas’ broad range of capabilities in screening and developing natural source-derived compounds with REGiMMUNE’s immune [...]
AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting - In Vitro and In Vivo Data Show AEZS-126 as Promising Oral Compound for
Future Clinical Development in Cancer
QUEBEC CITY, April 21 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today presented two posters on AEZS-126, a promising compound for clinical intervention of the PI3K/ [...]
Ligand and GlaxoSmithKline Collaboration Identifies New Lead Compound - SAN DIEGO, Mar 30, 2009 (BUSINESS WIRE) —-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND: 2.98, -0.14, -4.49%) today
announced that it has identified a new lead for advancement in its
alliance with GlaxoSmithKline (NYSE:GSK). This newly identified lead
compound is from a program being evaluated as a potential treatment for
[...]
Ligand and GlaxoSmithKline Collaboration Identifies New Lead Compound - SAN DIEGO, Mar 30, 2009 (BUSINESS WIRE) —-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND: 2.98, -0.14, -4.49%) today announced that it has identified a new lead for advancement in its alliance with GlaxoSmithKline (NYSE:GSK). This newly identified lead compound is from a program being evaluated [...]
New Model For Drug Discovery With Fluorescent Anesthetic Demonstrated - ScienceDaily (Apr. 8, 2009) — A collaboration of University of Pennsylvania and University of Wisconsin chemists and anesthesiologists have identified a fluorescent anesthetic compound that will assist researchers in obtaining more precise information about how anesthetics work in the body and will provide a means to more rapidly test new anesthetic compounds in the search [...]
New Drug Shows Promise In Treating Drug-resistant Prostate Cancer - ScienceDaily (Apr. 11, 2009) — A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.
Chemists and biologists at UCLA and colleagues at several other institutions, including Memorial Sloan-Kettering Cancer Center, have created a new drug to treat a particularly lethal [...]
|
|
